Jardiance Cost in Rhode Island 2026: Cash Price, Medicaid, and Compounded Empagliflozin Options

What Is the Cash Price of Jardiance in Rhode Island?

The manufacturer's wholesale acquisition cost for Jardiance sits at roughly $680 per month in 2026, a price that applies at most Rhode Island retail pharmacies when no insurance discount or coupon is active. Without any assistance program, a 30-day supply of either the 10 mg or 25 mg tablet costs essentially the same amount because Boehringer Ingelheim prices both strengths identically.

That list price has increased steadily since the drug's 2014 FDA approval for type 2 diabetes [1]. Empagliflozin belongs to the SGLT2 inhibitor class, which also includes dapagliflozin (Farxiga) and canagliflozin (Invokana). All three carry comparable list prices, but pharmacy-specific contracts mean actual retail cash prices vary by $20 to $60 across CVS, Walgreens, Rite Aid, and independent pharmacies in Providence, Warwick, and Cranston.

GoodRx and similar discount aggregators may show prices in the $450 to $530 range at certain Rhode Island locations when a coupon code is applied, though those discounts cannot be combined with insurance in the same transaction [2]. Patients paying entirely out of pocket should price-check at least three local pharmacies before filling.

The FDA label for Jardiance specifies that the drug is available only by prescription; no over-the-counter or behind-the-counter pathway exists [1]. Rhode Island law mirrors federal prescription-only classification, so any online source offering Jardiance without a valid prescription is operating outside the law.

Why Jardiance Costs What It Does: The Clinical Evidence Behind the Price

Jardiance carries a premium price partly because its cardiovascular outcome data are among the strongest in the SGLT2 class. EMPA-REG OUTCOME (N=7,020 patients with type 2 diabetes and established cardiovascular disease) showed a 38% relative risk reduction in cardiovascular death compared with placebo (10.1% vs. 3.7% absolute event rates at a median 3.1 years, P<0.001) [3]. That trial, published in the New England Journal of Medicine in 2015, changed prescribing guidelines globally and gave Boehringer Ingelheim and Lilly the evidence needed to justify a premium price point.

Subsequent trials extended the indications. EMPEROR-Reduced (N=3,730) demonstrated a 25% reduction in the composite of cardiovascular death or hospitalization for heart failure in patients with HFrEF (hazard ratio 0.75 to 95% CI 0.65 to 0.86, P<0.001) [4]. EMPEROR-Preserved (N=5,988) showed a 21% reduction in the same composite endpoint in patients with HFpEF (hazard ratio 0.79 to 95% CI 0.69 to 0.90, P<0.001) [5]. EMPA-KIDNEY (N=6,609) then confirmed a 28% reduction in the risk of kidney disease progression or cardiovascular death in patients with CKD (hazard ratio 0.72 to 95% CI 0.64 to 0.82, P<0.001) [6].

The FDA approved empagliflozin for heart failure regardless of ejection fraction and for CKD based on this body of data [1]. Each new approval strengthened the drug's market position and sustained its list price.

Rhode Island Medicaid Coverage for Jardiance

Rhode Island Medicaid (RIte Care and Rhody Health Options) covers Jardiance, but only after a prior authorization (PA) request is approved. The PA criteria typically require documentation of a type 2 diabetes diagnosis, an A1c above a specified threshold (generally 7.5% or higher on the plan's current criteria), evidence that metformin has been tried or is contraindicated, and, for the heart failure or CKD indications, specialist documentation confirming the diagnosis.

Prescribers in Rhode Island can submit PA requests electronically through the RI Medicaid provider portal or by fax. Processing time is 3 to 5 business days for standard requests and 24 hours for urgent clinical situations. Denials can be appealed; the appeal window under Rhode Island administrative rules is 30 calendar days from the denial notice.

The American Diabetes Association's 2024 Standards of Care state: "For patients with type 2 diabetes and established cardiovascular disease, heart failure, or CKD, an SGLT2 inhibitor with proven benefit should be used regardless of A1c or need for additional glucose lowering" [7]. That guideline language gives prescribers a strong clinical basis for PA appeals when Medicaid denies Jardiance for a patient with cardiovascular or renal indications.

Dual-eligible patients (Medicare and Medicaid) may access Jardiance through Medicare Part D plans operating in Rhode Island. The Extra Help (Low Income Subsidy) program can reduce cost sharing to $4.50 or $11.20 per fill for generic and brand drugs respectively in 2026 [8]. Empagliflozin has no FDA-approved generic formulation as of early 2025, so the brand cost-sharing tier applies.

Insurance Coverage for Jardiance in Rhode Island

Most commercial insurance plans sold in Rhode Island, including those offered by Blue Cross Blue Shield of RI, Neighborhood Health Plan of RI, and United Healthcare, place Jardiance on Tier 3 or Tier 4 of the formulary. That typically means a copay of $45 to $120 per 30-day fill after the deductible is met, though exact cost sharing depends on the specific plan design [9].

Patients whose plans cover Jardiance at Tier 3 or higher should ask their prescriber about step-therapy requirements. Many Rhode Island commercial plans require a 90-day trial of metformin, and sometimes one other oral agent, before approving Jardiance. For patients who already have heart failure or CKD, step-therapy exemptions are available under Rhode Island General Laws section 27-18.9, which mandates that insurers grant step-therapy exceptions when the required first-step drug is clinically contraindicated or has already been tried [10].

The Rhode Island Office of the Health Insurance Commissioner (OHIC) regulates commercial insurance formulary decisions and accepts consumer complaints. Patients denied coverage can file a complaint at ohic.ri.gov or request an independent external review under Rhode Island's external review statute.

The Boehringer Ingelheim / Lilly Jardiance Savings Card

For commercially insured Rhode Island patients who are not enrolled in any federal or state government health program, the Jardiance savings card from Boehringer Ingelheim and Lilly may bring out-of-pocket cost down to as low as $10 per 30-day fill. The card covers the gap between insurance reimbursement and up to a manufacturer-set monthly maximum benefit.

Eligibility rules matter. The savings card explicitly excludes patients covered by Medicare, Medicaid, CHIP, TRICARE, or any other federal or state health program. Rhode Island patients on RIte Care or Medicare Part D cannot use the card legally. Attempting to use a manufacturer card while enrolled in a government program constitutes federal healthcare fraud.

Eligible patients can enroll at jardiance.com or by calling the manufacturer's patient support line. The card is accepted at most Rhode Island retail pharmacies, including major chains and many independents. Once enrolled, the card renews annually and requires no income verification.

For uninsured Rhode Island patients who do not qualify for Medicaid, Boehringer Ingelheim's patient assistance program (BI Cares) may provide Jardiance at no cost. Income eligibility thresholds for BI Cares are updated annually; in 2025 the program covered households earning up to 400% of the federal poverty level [11].

Compounded Empagliflozin in Rhode Island: What Is Legal

Rhode Island permits licensed 503A compounding pharmacies to prepare empagliflozin compounds for individual patients with a valid prescription. Section 503A of the Federal Food, Drug, and Cosmetic Act governs these pharmacies and requires that each preparation be made for a specific patient based on a prescriber's order [12]. The compound must not be commercially available in the exact form or strength needed, and the pharmacy must be licensed in Rhode Island by the Board of Pharmacy.

Three practical points apply here. First, compounded empagliflozin is not FDA-approved; it has not undergone the bioequivalence, sterility, or stability testing required for brand-name or generic approval. Second, the FDA has not placed empagliflozin on any shortage list, which means 503B outsourcing facilities cannot legally compound it in bulk for office use or general distribution. Third, 503A pharmacies may compound it patient-by-patient if a prescriber documents a clinical reason the commercial product does not meet the patient's needs.

Telehealth prescribers operating in Rhode Island can write compounded empagliflozin prescriptions when they hold a valid Rhode Island medical license and have established a bona fide patient-provider relationship, including an appropriate medical evaluation [13]. The Rhode Island Board of Medical Licensure and Discipline requires that telehealth prescribers follow the same standard of care as in-person prescribers.

Cost for compounded empagliflozin varies widely by pharmacy and formulation. Cash prices at licensed 503A pharmacies in New England have ranged from $40 to $120 per month depending on dose and base, compared with $680 for brand Jardiance. Patients should verify that any compounding pharmacy holds a current Rhode Island Board of Pharmacy license before filling a prescription.

How Telehealth Prescribing Works for Jardiance in Rhode Island

Rhode Island telehealth law, codified at R.I. Gen. Laws section 27-81, requires that telehealth services meet the same standard of care as in-person services, but it does not require an initial in-person visit before prescribing [14]. A licensed Rhode Island provider can evaluate a patient via synchronous video, establish a diagnosis, and prescribe Jardiance or compounded empagliflozin in a single visit.

For Jardiance specifically, the prescriber must document a qualifying diagnosis (type 2 diabetes, heart failure, or CKD), review relevant labs (A1c, eGFR, urine albumin-to-creatinine ratio), screen for contraindications (eGFR <20 mL/min/1.73m² for the CKD indication; recurrent genitourinary infections; history of DKA), and counsel the patient on sick-day management and fluid intake [1].

HealthRX's Rhode Island-licensed providers can complete this evaluation by video and route the prescription to any Rhode Island retail pharmacy or a licensed 503A compounding pharmacy of the patient's choice. Follow-up labs, including a basic metabolic panel and repeat eGFR at 3 months, are standard of care after initiating empagliflozin [7].

Comparing the True Monthly Cost Across All Access Pathways in Rhode Island

The table below summarizes realistic monthly out-of-pocket estimates for a Rhode Island patient in 2026. These are estimates; actual costs depend on individual plan design, income, and pharmacy choice.

| Access Pathway | Estimated Monthly Cost | |---|---| | Cash price (no assistance) | $680 | | GoodRx or similar coupon at select pharmacies | $450 to $530 | | Commercial insurance, Tier 3 copay (post-deductible) | $45 to $120 | | Commercial insurance plus BI/Lilly savings card | As low as $10 | | RI Medicaid (approved PA) | $0 to $3 copay | | Medicare Part D + Extra Help | $11.20 or less | | BI Cares patient assistance (uninsured, income-eligible) | $0 | | Licensed 503A compounded empagliflozin (cash) | $40 to $120 |

Clinical Considerations That Affect Whether Jardiance Is the Right Choice

Before cost becomes the deciding factor, the prescriber and patient need to confirm that empagliflozin is clinically appropriate. The FDA label specifies that Jardiance should not be used in patients with type 1 diabetes, in those with eGFR <20 mL/min/1.73m², or in pregnant patients [1]. The label carries a warning about lower-limb amputation risk (though the signal is stronger for canagliflozin than empagliflozin based on CANVAS vs. EMPA-REG data) [15] and a Fournier's gangrene warning that applies to the SGLT2 class as a whole [16].

The 2023 ACC/AHA heart failure guidelines give empagliflozin a Class I recommendation for patients with HFrEF and a Class IIa recommendation for HFpEF, noting that "SGLT2 inhibitors reduce the risk of worsening heart failure and cardiovascular death" [17]. For patients with CKD and a urine albumin-to-creatinine ratio above 200 mg/g, KDIGO 2024 guidelines recommend an SGLT2 inhibitor as first-line kidney-protective therapy alongside an ACE inhibitor or ARB [18].

Weight and blood pressure effects are secondary benefits worth discussing with patients. EMPA-REG OUTCOME participants lost a mean of 2.2 kg and saw systolic blood pressure drop by 3.97 mmHg versus placebo over 3.1 years [3]. Those effects are modest compared with GLP-1 receptor agonists, but they are additive when both drug classes are combined [19].

Genital mycotic infections affect roughly 6% to 8% of women and 3% to 4% of men on empagliflozin versus placebo in clinical trials [3]. Patients should be counseled on hygiene and the importance of reporting symptoms early.

Step-By-Step Plan to Minimize Jardiance Cost in Rhode Island

Start with your insurance formulary. Call the member services number on your insurance card and ask specifically whether Jardiance is covered, what tier it is on, and whether a step-therapy exemption applies given your diagnosis.

If you have commercial insurance, enroll in the BI/Lilly savings card at jardiance.com before your first fill. The card can be applied immediately.

If you have Rhode Island Medicaid, ask your prescriber to submit a prior authorization with documentation of your diagnosis, current A1c, eGFR, and any cardiovascular or renal comorbidities. Reference the ADA 2024 Standards of Care [7] in the PA submission if the indication is heart failure or CKD.

If you are uninsured and income-eligible, apply to BI Cares at the manufacturer's website before paying out of pocket. Processing takes 2 to 4 weeks for the first approval.

If cost remains a barrier after exhausting all of the above, ask a licensed Rhode Island provider about compounded empagliflozin through a 503A pharmacy. Confirm the pharmacy's Rhode Island license number on the Board of Pharmacy's public registry before submitting the prescription.

Do not stop Jardiance abruptly without medical guidance, especially if you have heart failure or CKD. Discontinuation has been associated with a rebound rise in eGFR followed by accelerated kidney function decline in some observational data [20].